Matthew Gall was appointed as our Chief Financial Officer in April 2026. Mr. Gall previously served as Chief Financial Officer of Kalaris Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company, from November 2025 to April 2026. Mr. Gall served as the Chief Financial Officer of iTeos Theraputics, Inc. (NASDAQ: ITOS), a clinical-stage biopharmaceutical company, from June 2020 to August 2025, and held roles of increasing responsibility at Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biotechnology company, from January 2012 to June 2020. Mr. Gall holds a B.S. in Business Administration from Bowling Green State University and an M.B.A. from the University of Chicago Booth School of Business.